Jessie Villanueva

Jessie Villanueva

UNVERIFIED PROFILE

Are you Jessie Villanueva?   Register this Author

Register author
Jessie Villanueva

Jessie Villanueva

Publications by authors named "Jessie Villanueva"

Are you Jessie Villanueva?   Register this Author

34Publications

782Reads

31Profile Views

PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.

Pigment Cell Melanoma Res 2019 Nov 6. Epub 2019 Nov 6.

Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12845DOI Listing
November 2019

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.

Pigment Cell Melanoma Res 2019 09 20;32(5):687-696. Epub 2019 May 20.

Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697571PMC
September 2019

COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.

Melanoma Manag 2017 Dec 21;4(4):183-186. Epub 2017 Nov 21.

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2017-0023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959291PMC
December 2017

Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF Conformation.

ACS Chem Biol 2016 10 6;11(10):2876-2888. Epub 2016 Sep 6.

Department of Biochemistry and Biophysics and the Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania , 421 Curie Blvd., Philadelphia, Pennsylvania 19104, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschembio.6b00529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108658PMC
October 2016

Playing Polo-Like Kinase in NRAS-Mutant Melanoma.

J Invest Dermatol 2015 Oct;135(10):2352-2355

The Wistar Institute, Molecular and Cellular Oncogenesis Program & Melanoma Research Center, Philadelphia, Pennsylvania, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2015.253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568563PMC
October 2015

Development of organometallic S6K1 inhibitors.

J Med Chem 2015 Jan 13;58(1):305-14. Epub 2014 Nov 13.

The Wistar Institute , 3601 Spruce Street, Philadelphia, Pennsylvania 19104, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm5011868DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289024PMC
January 2015

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Cancer Discov 2013 Dec 8;3(12):1378-93. Epub 2013 Oct 8.

1Tumor Metastasis and Microenvironment Program and 2Molecular and Cellular Oncogenesis Program, The Wistar Institute; 3Abramson Cancer Center, University of Pennsylvania, Philadelphia; 4Lehigh Valley Health Network, Allentown, Pennsylvania; 5The National Institute on Aging, NIH, Baltimore, Maryland; and 6Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918498PMC
December 2013

Highlights of the 2012 Congress of the Society for Melanoma Research, 8-11 November 2012, Hollywood, CA.

Melanoma Res 2013 Jun;23(3):237-40

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3283610528DOI Listing
June 2013

A modified HSP70 inhibitor shows broad activity as an anticancer agent.

Mol Cancer Res 2013 Mar 9;11(3):219-29. Epub 2013 Jan 9.

Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-12-0547-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606282PMC
March 2013

Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.

Adv Pharmacol 2012 ;65:335-59

Molecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-397927-8.00011-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677516PMC
February 2013

Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.

Int J Cancer 2012 Nov 15;131(9):2165-74. Epub 2012 Mar 15.

Department of Gynecology and Obstetrics, the National Centre of Tumor Disease, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.27476DOI Listing
November 2012

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.

Cancer Res 2011 Dec;71(23):7137-40

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-1243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588168PMC
December 2011

Sorting through the many opportunities for melanoma therapy.

Pigment Cell Melanoma Res 2011 Oct;24(5):975-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1755-148X.2011.00906.xDOI Listing
October 2011

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Clin Cancer Res 2011 Apr 29;17(7):1658-63. Epub 2011 Mar 29.

Program of Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-0174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079374PMC
April 2011

Will engineered T cells expressing CD20 scFv eradicate Melanoma?

Mol Ther 2011 Apr;19(4):638-40

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/mt.2011.46DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070110PMC
April 2011

BRAF inhibitor unveils its potential against advanced melanoma.

Cancer Cell 2010 Oct;18(4):301-2

The Wistar Institute, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2010.10.001DOI Listing
October 2010

Melanoma and the tumor microenvironment.

Curr Oncol Rep 2008 Sep;10(5):439-46

The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662003PMC
http://dx.doi.org/10.1007/s11912-008-0067-yDOI Listing
September 2008

ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

Mol Biol Cell 2007 Apr 21;18(4):1457-63. Epub 2007 Feb 21.

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6084, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1091/mbc.e06-10-0908DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1838994PMC
April 2007